title: [Cellex in the treatment of patients with acute disturbance of cerebral blood circulation: results of a multicenter comparative open clinical trial].
abstract: OBJECTIVE
  To evaluate efficacy and tolerability of cellex in the treatment of patients with acute disturbance of cerebral blood circulation (ADCBC) used in the clinical practice in the Russian Federation.
  
  
  METHODS
  A trial included 178 patients with ADCBC from 6 Russian clinical centers, 146 (82%) patients were diagnosed with ischemic stroke and 32 (18%) with hemorrhagic stroke in the age of 35-80 years.
  
  
  RESULTS
  One hundred and sixty-six patients have completed the trial. The better outcome with the decrease of motor, visual, speech and sensory disorders was found after 4-week treatment.
  
  
  CONCLUSIONS
  Cellex may be recommended for treatment in acute and early rehabilitation stages of ADCBC.
authors.forename: N V
authors.initials: NV
authors.lastname: Pizova
authors.forename: M A
authors.initials: MA
authors.lastname: Sokolov
authors.forename: I A
authors.initials: IA
authors.lastname: Izmaĭlov
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000818:Animals; D002560:Cerebrovascular Circulation / Q000187:drug effects; D045424:Complex Mixtures / Q000627:therapeutic use; D005260:Female; D006801:Humans; D020300:Intracranial Hemorrhages / Q000188:drug therapy* / Q000534:rehabilitation; D008297:Male; D008875:Middle Aged; D010455:Peptides / Q000627:therapeutic use*; D011506:Proteins / Q000627:therapeutic use*; D012426:Russia; D020521:Stroke / Q000188:drug therapy*; D000071939:Stroke Rehabilitation; D013552:Swine
chemical_list: D045424:Complex Mixtures; D010455:Peptides; D011506:Proteins